Embodiments disclosed herein relate to magnetic nanoparticles having a non-narcotic analgesic, as well as methods of preparation and use thereof. A magnetically response pharmaceutical can include a core region having magnetic nanoparticles (MNPs) and a protein-based analgesic. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe.sub.3O.sub.4, as well as compositions containing HSS.

The present invention relates to a method of preparing a black phosphorus nanosheet and application, belonging to the technical field of functional material production. In the method, the black phosphorus sheet is used as the electrolytic anode, and an electrochemical reaction system is constructed together with an inert electrode and an alkaline aqueous electrolyte, wherein the alkaline aqueous electrolyte comprises an N-N dimethylformamide solution dissolved with epoxy resin. In alkaline aqueous electrolyte, the prepared black phosphorus nanosheet structure tends to be more stable, not easy to be damaged and the oxidation degree is reduced. Under alkaline conditions, it is conducive to improve the intercalation and stripping effect of black phosphorus material of anode and make the black phosphorus exfoliation more complete.

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

A silicified cell includes a nanoparticle that carries a bioactive agent. The silicified call can be a tumor cell, a bacterial cell, a virus, or a silicifiable compartment or fragment thereof. The silicified cell can optionally include an immunomodulatory moiety that may be carried within pores of the nanoparticle and/or bound to the surface of the nanoparticle. The silicified cell can be used as a prophylactic or therapeutic treatment for treating tumors or bacterial infections.

Provided are a nanocomposite including a nano-drug delivery system; and a ginseng extract or a ginsenoside isolated therefrom, and a preparation method thereof, in which the nanocomposite may be used for the prevention or treatment of cancer and inflammatory diseases. The metal nanocomposite of the present invention may be prepared in a uniform size without using an additional reducing agent or stabilizing agent in a significantly shortened time, as compared with known metal nanoparticles. Further, since the metal nanocomposite has high solubility in water and high targeting ability for cancer cells, it can be advantageously developed as drugs. Further, the metal nanocomposite exhibits high anti-cancer and anti-inflammatory activities, and thus may be usefully applied to prevention or treatment of cancer and inflammatory diseases. Furthermore, the metal nanocomposite exhibits anti-microbial activity, biofilm-degrading activity, and anti-coagulant activity, and thus may be applied to a variety of industrial fields.

The kaolinite composite diagnostic and therapeutic agent uses modified kaolinite as a carrier and is loaded with carbon nitride quantum dots and doxorubicin. The present disclosure provides a preparation method of the kaolinite composite diagnostic and therapeutic agent, including the following steps: S1: preparing the modified kaolinite by subjecting the pharmaceutical grade kaolinite to intercalation, exfoliation, and immersion wet etching; S2: subjecting the modified kaolinite and a carbon nitride quantum dot solution to ultrasonication, drying, and grinding to obtain a kaolinite composite containing the carbon nitride quantum dots; and S3: dissolving the doxorubicin in the dark, adding dissolved doxorubicin into the kaolinite composite containing the carbon nitride quantum dots, shaking in the dark for a period of time, and washing and drying to obtain the diagnostic and therapeutic agent containing the carbon nitride quantum dots and the doxorubicin.

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core-shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.

Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density.